DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161891

Indications for intravitreal anti vascular endothelial growth factor in Kano, North Western, Nigeria

Abdulsalam Shuaib, Sadiq Hassan

Abstract


Background: To review the common indications for intravitreal anti vascular endothelial growth factor (VEGF) medications given at the retinal unit of Makkah Specialist Eye Hospital, Kano, Nigeria from January 2014 to December 2015.

Methods: The case records of all patients given intravitreal anti VEGF medications were reviewed and age, diagnosis and indication for injection were recorded. Results were analyzed using the PAWS statistics version 18.0 (SPSS Inc., Chicago, IL).

Results: A total of 174 injections consisting of 170 bevacizumab and 4 ranibizumab injections were given in the study period. The common indications for intravitreal injections were diabetic macula edema (42.5%), retinal vein occlusion (25.9%) and vitreous heamorrhage (9.8%).

Conclusions: Diabetic macula edema and retinal vein occlusions are the major indications for intravitreal anti VEGF injections in Kano.


Keywords


Diabetic macula edema, Retinal vein occlusion, Intravitreal anti VEGF

Full Text:

PDF

References


Aiello LP, Avery RL, Arrigg PG. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7.

CATT Research Group, Martin DF, Meguire MG. Ranibizumab and bevacizumab for neovascular age related macula degeneration. N Engl J Med. 2011;364(20):1897-908.

World Health Organization (WHO) programme for the prevention of blindness and deafness. Global initiative for elimination of avoidable blindness. WHO/PBL/2000; 97.61Rev.2.

Kyari F, Tafida A, Sivasubramanian S, Marthy GV, Peto T, Gilbert CE. Prevalence and risk factors for diabetes and diabetic retinopathy. Results from Nigeria national blindness and visual impairment Study. BMC Public Health. 2014;14:1299.

Massin P, Bandello F, Garweg JG. Safety and efficacy of ranibizumab in diabetic macular edema (Resolve Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes care. 2010;33:2399-405.

Mitchell P, Bandello F, Schmidt-Erfurth U. The Restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25.

Michaelides M, Kaines A, Hamilton RD. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt study) 12-month data: report 2. Ophthalmology. 2010;117:1078-86.

Oluleye TS, Babalola Y. Indications for intravitreal bevacizumab in Ibadan, Sub Saharan Africa. Open Ophthalmol J. 2014;8:87-90.

Campochiaro PA, Heier JS, Feiner L. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.

Brown DM, Campochiaro PA, Singh RP. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology. 2010;117:1124-33.

Oluleye TS. Is age related macular degeneration a problem in Ibadan, Sub Sharan Africa? Clin Ophthalmol. 2012;6:561-4.

Avery RL. Regression of retinal and iris neovascularization following intravitreal bevacizumab. Retina. 2006;26:352-4.